Tamtam Try Tamtam free
Zoetis logo

Zoetis account plan

Advancing animal health care

At a glance

Zoetis makes medicines, vaccines and diagnostics for pets and livestock: $9,467 million 2025 revenue, about 14,500 employees.

Zoetis, headquartered in Parsippany, New Jersey and a former Pfizer business unit, discovers, makes and sells animal health medicines, vaccines, diagnostics and biodevices for dogs, cats, horses, cattle, swine, poultry, fish and sheep. Its products are mostly prescription products sold through veterinarians and distributors, marketed directly in approximately 45 countries and sold in more than 100. FY2025 revenue was $9,467 million (+2%) and net income attributable to Zoetis $2,673 million. It had about 14,500 employees at 31 December 2025 and is led by CEO Kristin C. Peck.

Business units

Strategic priorities

Defending dermatology and parasiticide share
Leverage portfolio diversity where share pressure is most acute, with Apoquel Chew conversion, gross-to-net promotions and bundling while protecting list price; U.S. derm share loss slowed to 4 points in Q3 2026 from about 7 in Q2.
Expanding access to established franchises
Medical affairs and the new Zoetis Medical Hub, Simparica Duo expected as a new Rx product, and Lenivia and Portela broadening OA pain options.
Innovation pipeline
A significant major market approval every year for several years, long-acting Cytopoint launching in the first half of next year, and new categories targeted: chronic kidney disease, oncology, cardiology, obesity, diabetes and anxiety.
Cost and productivity program
A comprehensive cost and productivity program focused on cost of goods and SG&A, with restructuring costs of $142 million over the first nine months of 2026.
ERP transition
A multi-year move to a new ERP system, starting with eliminating the one-month reporting lag for international subsidiaries from 1 January 2026.

Latest results

Q3 2026 revenue was $2,391 million against $2,422 million (-1% reported, -2% operational), as lower net price, lower key franchise volume and the MFA divestiture outweighed growth elsewhere. Net income attributable to Zoetis fell 18% to $591 million, while adjusted diluted EPS was $1.75 versus $1.70 on a lower share count. Key dermatology sales fell 16% globally to $396 million, while livestock rose 7% to $797 million and companion animal diagnostics 13%. Full-year 2026 guidance is revenue of $9.22 billion to $9.32 billion and adjusted diluted EPS of $6.25 to $6.35, with a sequential high-single-digit revenue decline expected in Q4.

Investments and deals

Diagnostics acquisitions
Veterinary Pathology Group (diagnostic laboratories in the U.K. and Ireland) in 2025 and VitalRADS, a veterinary teleradiology platform, in Q3 2026.
Research and development
R&D spending of $698 million in 2025 across more than 300 programs, with a pipeline the CEO says has 12 potential blockbusters.
Capital expenditure
Capex of $621 million in 2025 and $334 million in the first nine months of 2026, against $462 million a year earlier.
Share buybacks
23.9 million shares repurchased for $3.2 billion in 2025, partly funded by $2.0 billion of convertible notes; $2.4 billion returned through buybacks and dividends in 2026 through Q3.

Challenges and risks

New competition in dermatology
New entrants use discounting, rebates and bundling to compete for existing patients; key dermatology sales fell 16% in Q3 2026.
Fewer veterinary visits
U.S. clinic visits are down 3% year-to-date across categories, as veterinary service costs have risen 50% since 2022.
Generic competition
Generics hit Convenia and Cerenia in the U.S., and Draxxin's U.S. sales have declined 66% since 2021.
Price pressure
Price realization for 2026 is expected at 0% to -1%, and Q3 2026 net price fell about 1%.
Tariffs, FX and debt
Tariffs may hurt demand and raise costs, about 45% of nine-month 2026 revenue was in foreign currencies, and the company carries about $9.2 billion of unsecured notes.

What leadership says

“Zoetis has built leading categories before. We know how to defend them, evolve them, and build what comes next.”

Kristin C. Peck, Chief Executive Officer · Zoetis Q2 2026 earnings call, 2026-08-06

“taking costs out where needed to operate more efficiently while protecting investments in innovation”

Kristin C. Peck, Chief Executive Officer · Zoetis Q3 2026 earnings call, 2026-11-05

“veterinary service costs have risen 50% since 2022”

Kristin C. Peck, Chief Executive Officer · Zoetis Q3 2026 earnings call, 2026-11-05, on the pet market

Where a supplier can help

Cost and productivity savings
The comprehensive cost and productivity program targets cost of goods and SG&A; procurement, manufacturing efficiency and automation suppliers can tie their offer to it.
ERP and finance transformation
The multi-year ERP transition and the reporting alignment of international subsidiaries create work for ERP integrators, finance process and data migration partners.
Commercial effectiveness and direct-to-consumer marketing
Defending dermatology and parasiticide share relies on clinic promotions, bundling and point-of-sale direct-to-consumer advertising; marketing analytics and trade promotion tools fit that priority.
Diagnostics growth
With diagnostics described as a strategic enabler and VPG and VitalRADS acquired, laboratory, imaging and data platform suppliers can support integration and scale.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Zoetis?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Zoetis

What does Zoetis do?

Zoetis develops, makes and sells medicines, vaccines, diagnostics and biodevices for companion animals and livestock, mostly sold through veterinarians.

What is Zoetis's revenue?

FY2025 revenue was $9,467 million, up 2%. For 2026 Zoetis guides revenue of $9.22 billion to $9.32 billion.

How many employees does Zoetis have?

About 14,500 employees at 31 December 2025, about 6,800 in the U.S. and 7,700 elsewhere.

Who leads Zoetis?

Kristin C. Peck is CEO, and Jay Saccaro joined as EVP, Chief Financial Officer and Chief Operating Officer in 2026.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)